地奥司明片联合盐酸坦索罗辛缓释胶囊治疗Ⅲ_B型前列腺炎的临床研究

Clinical application of combination therapy of Diosmin plus Tamsulosin in the treatment of type Ⅲ_B chronic prostatitis

目的:观察并评估地奥司明片联合盐酸坦索罗辛缓释胶囊治疗Ⅲ_B型前列腺炎的临床疗效及用药安全。方法:将162例Ⅲ_B型前列腺炎患者随机分成对照组和观察组两组,对照组患者予以盐酸坦索罗辛缓释胶囊治疗,观察组予以地奥司明片联合盐酸坦索罗辛缓释胶囊治疗,治疗前及治疗后2个月分别对所有患者进行美国国立卫生研究院慢性前列腺炎症状指数评分(NIH-CPSI),包括疼痛不适评分、排尿症状评分以及生活质量评分,比较两组的临床疗效及不良反应的发生情况。结果:对照组及观察组患者经过治疗以后NIH-CPSI评分结果均较治疗前明显改善,其差异有统计学意义(P<0.05);其中观察组的总体显效率及总体有效率均较对照组显著升高(P<0.05),而不良反应发生率差异无统计学意义(P>0.05)。结论:地奥司明片联合盐酸坦索罗辛缓释胶囊治疗Ⅲ_B型前列腺炎较坦索罗辛单药治疗效果更为显著,能显著提高临床疗效,改善患者生活质量,而不显著增加不良反应的发生率,具有很大的临床推广及应用价值。

Objective： To evaluate the efficacy and safety of combination therapy of Diosmin tablet plus Tamsu- losin Hydrochloride sustained release capsule in the treatment of type ⅢB chronic prostatitis. Method： One hun- dred and sixty-two patients who have been diagnosed as type Ⅲ B chronic prostatitis were randomly divided into two groups. The control group was treated with Tamsulosin Hydrochloride sustained release capsule, while the observation group was treated with combination therapy of Diosmin tablet and Tamsulosin Hydrochloride sustained release capsule. The efficacy between two groups was evaluated by US National Institutes of Health Chronic Pros- tatitis Symptom Index （NIH-CPSI） before and after two months treatment. Meanwhile, the side effects were also compared. Result： After two months treatment, the overall efficiency and total effective rate of observation group were significantly higher than those of the control group, respectively （34.5% vs 18.5M and 86.4% vs 61.7%, P d0.05）. Meanwhile, there was no significant difference in the incidence of side effects between two groups （ P〉0.05）. Conclusion： The combination therapy of Diosmin tablet plus Tamsulosin Hydrochloride sustained release capsule has an improving efficacy and favorable safety in patients with type Ⅲ B chronic prostatitis compared with Tamsulosin used alone.